Loading...
•
Mar 31, 2022
Omeros Q1 2022 Earnings Report
Omeros reported first quarter 2022 financial results.
Key Takeaways
Omeros Corporation reported a net loss of $33.0 million for the first quarter of 2022. The company earned royalties of $13.8 million from Rayner's net sales of OMIDRIA. Omeros had $142.2 million in cash, cash equivalents and short-term investments as of March 31, 2022.
Omeros earned $13.8 million in royalties from Rayner's OMIDRIA sales in Q1 2022.
Net loss for the quarter was $33.0 million, or $0.53 per share.
Omeros had $142.2 million in cash, cash equivalents, and short-term investments as of March 31, 2022.
The company is pursuing formal dispute resolution with the FDA regarding narsoplimab approval.
Omeros
Omeros
Forward Guidance
Omeros anticipates value-creating events throughout the remainder of 2022.
Positive Outlook
- OMS906 data in patients with paroxysmal nocturnal hemoglobinuria
- Data from our efforts in COVID-19
- Updates on our Phase 1 study evaluating our long-acting MASP-2 inhibitor OMS1029
- Completion of enrollment for the proteinuria endpoint in our narsoplimab ARTEMIS-IgAN trial
- Potential to earn an OMIDRIA-related $200-million commercial milestone payment